Compare Quest Diagnostics Inc (DGX) vs iShares iBoxx $ High Yield Corporate Bond ETF (HYG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs iShares iBoxx $ High Yield Corporate Bond ETF — how do they compare? Quest Diagnostics Inc trades at $237.51 (market cap $26.21B), while iShares iBoxx $ High Yield Corporate Bond ETF trades at $79.62. The key difference: Quest Diagnostics Inc pays a 1.45% dividend while iShares iBoxx $ High Yield Corporate Bond ETF pays none, and Quest Diagnostics Inc is trading nearer its 52-week high, iShares iBoxx $ High Yield Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| DGX | HYG | |
|---|---|---|
Market Cap | $26.21B | — |
Sector | Health | Fixed Income |
52-Week High | $238.50 | $81.32 |
52-Week Low | $173.49 | $78.72 |
Enterprise Value | $31.97B | — |
Dividend Yield | 1.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.24, down 0.16% on the day, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $3.12 and raising its full-year outlook, driven by robust testing demand. Revenue grew to $11.04B in 2025, with net income of $992M, though margins face pressure from lower-margin deals and rising costs.
The outlook is positive due to raised guidance and AI integration enhancing efficiency, but risks include debt levels and margin compression. Analysts maintain a cautious buy stance with a $249.50 price target, indicating modest upside potential from current levels amid competitive and cost challenges.
HYG, the iShares iBoxx $ High Yield Corporate Bond ETF, trades at $79.63 with minimal daily movement (+0.19%). Technical indicators show a bearish trend with moving averages signaling caution, while oscillators remain neutral. Recent news highlights investor rotation into fixed income ETFs amid rising yields, though specific articles question HYG's competitiveness versus peers on expenses and performance.
The outlook for HYG is clouded by bearish technicals and mixed sentiment. Opportunities exist from high-yield demand, but risks include rising interest rates, inflation fears, and underperformance versus alternatives. Investors should weigh the ETF's 6.5% yield against potential downside from economic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About iShares iBoxx $ High Yield Corporate Bond ETF
HYG is the world's largest high-yield bond ETF, tracking the Markit iBoxx USD Liquid High Yield Index. It provides liquid exposure to non-investment grade corporate debt, with 2026 top holdings including Cloud Software Group and Medline.
Read more on HYG →
